The importance of serum reduction for Vaccine developers

This whitepaper details a comprehensive analysis comparing serum-free and serum-supplemented media for vaccine development, with a focus on three widely utilized cell lines: Vero, MDCK, and MR-5. We examine the advantages of reducing serum dependency in vaccine production, address crucial factors such as cost-efficiency, supply stability, and regulatory approval facilitation. This study conducted demonstrates that serum reduced and serum-free media offer comparable or enhanced performance while minimizing the requirement for serum supplementation.

The whitepaper research reveals that Gibco™ VP-SFM (serum-free medium) significantly enhances Vero cell growth compared to conventional serum-supplemented media. Similarly, serum-free media exhibit equivalent or improved support for the growth of adherent MDCK cells in comparison to serum-containing alternatives. Furthermore, serum-free media demonstrate promising outcomes for nurturing MRC-5 cells, despite their inherent limited division capacity.

The study substantiates that serum-free and serum-reduced media yield similar or improved cell growth rates and virus titers relative to serum-supplemented media. These alternatives provide the inherent benefits of reducing serum dependency, enhancing supply chain security, and streamlining downstream process development. However, the successful implementation of serum-free media depends on various factors, including the specific cell line under consideration and the careful optimization of the media formulation.

Key Learnings:

• Serum-free and serum-reduced media can achieve similar or better cell growth and virus titers compared to serum-supplemented media in Vero, MDCK, and MRC-5 cell lines.
• Adherent Vero cells can be successfully adapted to suspension culture in a serum-free, animal origin-free (AOF) medium, resulting in high-yield virus production and reduced production costs.
• Serum-free media, such as Gibco™ OptiPRO™ SFM, can support the growth of adherent MDCK cells, providing an alternative to serum-containing media for influenza vaccine production.
• Serum-reduced and serum-free media, specifically designed for human diploid cells like MRC-5, can maintain high cell growth and virus titers while reducing serum usage by up to 90%.

Unlock vaccine development advantages with serum-free media: read our whitepaper for improved cell growth, reduced serum dependency, and streamlined process development.

Discover vaccine development advantages with serum-free media: read our whitepaper for improved cell growth, reduced serum dependency, and streamlined process development."